Clinical Trials
41 trialsIvosidenib as Maintenance Therapy in Transplant-Ineligible IDH1-mutated AML and HR-MDS
Ruijin Hospital
Personalized NK Cell Therapy in CBT
M.D. Anderson Cancer Center
N01-A-PICIT-GI
Peking University People's Hospital
N01-A-PICIT-GT
Peking University People's Hospital
Safety and Efficacy of Umbilical Cord Blood Therapy for Cancer Therapy-Induced Thrombocytopenia (CTIT)
Zhejiang Cancer Hospital
MYELO-CAN:TXA
University of Manitoba
A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)
Memorial Sloan Kettering Cancer Center
MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies
Masonic Cancer Center, University of Minnesota
Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Efficacy and Safety of Hetrombopag in Preventing Chemotherapy-induced Thrombocytopenia in Gastrointestinal Tumors
Changhai Hospital
MORE
Dana-Farber Cancer Institute
ACCELERATE
Center for International Blood and Marrow Transplant Research
Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders
Memorial Sloan Kettering Cancer Center
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
M.D. Anderson Cancer Center
ASPIRE
Wake Forest University Health Sciences
VTE-POG
University of Vermont Medical Center
Canakinumab for the Prevention of Progression to Cancer in Patients With Clonal Cytopenias of Unknown Significance, IMPACT Study
Ohio State University Comprehensive Cancer Center
Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation
Ohio State University Comprehensive Cancer Center
A Study of Emapalumab for Pediatric Aplastic Anemia
Memorial Sloan Kettering Cancer Center
ANC-IIT-004
Affiliated Hospital of Nantong University
IAMFIT
Children's Hospital of Philadelphia
Herombopag Treated T-DM1 Induced Platelet Reduction
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
RAFA
Children's Hospital Medical Center, Cincinnati
Two Step Haplo With Radiation Conditioning
Thomas Jefferson University
Efbemalenograstim Alfa for Primary/Secondary Prevention in Patients With Solid Tumors at High Risk for Febrile Neutropenia (FN) or Intermediate Risk of Chemotherapy Regimens Associated With Other Risk Factors in FN
Henan Cancer Hospital
COBRA
VA Office of Research and Development
AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion
New York Medical College
Romiplostim N01 for Chemotherapy-induced Thrombocytopenia
Institute of Hematology & Blood Diseases Hospital, China
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
Masonic Cancer Center, University of Minnesota
Oral-ATO for TP53-mutated Myeloid Malignancies
The University of Hong Kong
Anti-NKG2A Monoclonal Antibody for AML or MDS Patients Undergoing Haploidentical Transplantation
Istituto Clinico Humanitas
Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer
Okayama University
Eltrombopag for Chemotherapy-induced Thrombocytopenia
Institute of Hematology & Blood Diseases Hospital, China
Avatrombopag for Chemotherapy-induced Thrombocytopenia
Institute of Hematology & Blood Diseases Hospital, China
Herombopag for Chemotherapy-induced Thrombocytopenia
Institute of Hematology & Blood Diseases Hospital, China
SAL-0951 in the Treatment of Chemotherapy-induced Anemia in Patients With Non-myeloid Malignancies
Shenzhen Salubris Pharmaceuticals Co., Ltd.
Repurposing Metformin As a Leukemia-preventive Drug in CCUS and LR-MDS
Rigshospitalet, Denmark
PTCA199-4
Fudan University
Hetrombopag for the Thrombocytopenia Induced by Concurrent Chemoradiotherapy
Sir Run Run Shaw Hospital
Ibrutinib for the Treatment of AIHA in Patients With CLL/SLL or CLL-like MBL
Gruppo Italiano Malattie EMatologiche dell'Adulto
Iron Isomaltide for Iron-deficiency Anemia Patients With Locally Advanced Nasopharyngeal Carcinoma
Sun Yat-sen University